Journal of Breast Cancer最新文献

{"title":"Anatomy Versus Physiology: Is Breast Lymphatic Drainage to the Internal Thoracic (Internal Mammary) Lymphatic System Clinically Relevant?","authors":"Priscilla Machado, Ji-Bin Liu, Laurence Needleman, Christine Lee, Flemming Forsberg","doi":"10.4048/jbc.2023.26.e16","DOIUrl":"10.4048/jbc.2023.26.e16","url":null,"abstract":"<p><p>Approximately 15%-25% of breast lymphatic drainage passes through the internal thoracic (internal mammary) lymphatic system, draining the inner quadrants of the breast. This study aimed to use lymphosonography to identify sentinel lymph nodes (SLNs) in the axillary and internal thoracic lymphatic systems in patients with breast cancer. Seventy-nine patients received subcutaneous ultrasound contrast agent injections around the tumor. Lymphosonography was used to identify SLNs. In 14 of the 79 patients (17.7%), the tumor was located in the inner quadrant of the breast. Lymphosonography identified 217 SLNs in 79 patients, averaging 2.7 SLNs per patient. The 217 identified SLNs in the 79 patients were located in the axillary lymphatic system; none were located in the internal thoracic (internal mammary) lymphatic system, although it was expected in two to four patients (i.e., 4-11 SLNs). These results implied that SLNs associated with breast cancer are predominantly located in the axillary lymphatic system.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":"26 3","pages":"286-291"},"PeriodicalIF":2.2,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/56/d6/jbc-26-286.PMC10315328.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10341794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fertility Preservation in Young Women With Breast Cancer: A Review.","authors":"Yeon Hee Hong,&nbsp;Changhee Park,&nbsp;Haerin Paik,&nbsp;Kyung-Hun Lee,&nbsp;Jung Ryeol Lee,&nbsp;Wonshik Han,&nbsp;Seho Park,&nbsp;Seockhoon Chung,&nbsp;Hee Jeong Kim","doi":"10.4048/jbc.2023.26.e28","DOIUrl":"https://doi.org/10.4048/jbc.2023.26.e28","url":null,"abstract":"<p><p>Fertility preservation is a major concern in young patients diagnosed with breast cancer and planning to receive multimodality treatment, including gonadotoxic chemotherapy with or without age-related decline through long-term endocrine therapy. Most breast cancer patients undergo multimodality treatments; many short-term and long-term side effects arise during these therapies. One of the most detrimental side effects is reduced fertility due to gonadotoxic treatments with resultant psychosocial stress. Cryopreservation of oocytes, embryos, and ovarian tissue are currently available fertility preservation methods for these patients. As an adjunct to these methods, <i>in vitro</i> maturation or gonadotropin-releasing hormone agonist could also be considered. It is also essential to communicate well with patients in the decision-making process on fertility preservation. It is essential to refer patients diagnosed with breast cancer on time to fertility specialists for individualized treatment, which may lead to desirable outcomes. To do so, a multimodal team-based approach and in-depth discussion on the treatment of breast cancer and fertility preservation is crucial. This review aims to summarize infertility risk related to currently available breast cancer treatment, options for fertility preservation and its details, barriers to oncofertility counseling, and psychosocial issues.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":"26 3","pages":"221-242"},"PeriodicalIF":2.4,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/64/be/jbc-26-221.PMC10315332.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9741778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary Breast Small Cell Carcinoma With Merkel Cell Features: A Case Report and Literature Review.","authors":"Ya Jiang,&nbsp;Ziran Gao,&nbsp;Yuanyuan Wang,&nbsp;Wenmang Xu","doi":"10.4048/jbc.2023.26.e24","DOIUrl":"https://doi.org/10.4048/jbc.2023.26.e24","url":null,"abstract":"<p><p>Neuroendocrine carcinoma of the breast is a rare malignant tumor which, with the features of Merkel cells is even rarer. Herein, we report a case of small cell carcinoma with Merkel cell features in a 52-year-old female. Microscopically, the tumor was characterized by diffuse and consistent small round cells that were de-adherent. The tumor cells had round or oval nuclei with delicate chromatin and small nucleoli, the cytoplasm was sparse and eosinophilic. Additionally, the tumor was accompanied by high-grade ductal carcinoma in situ. Immunohistochemical staining showed that infiltrating tumor cells were positive for neuroendocrine markers, and punctately positive for CK20. The patient underwent modified radical mastectomy, axillary lymph node dissection, and postoperative adjuvant chemotherapy. No recurrence or metastasis was observed during follow-up period. Primary breast small cell carcinoma with Merkel cell features is rare and easily misdiagnosed as Merkel cell carcinoma. Early diagnosis and treatment may improve patient prognosis.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":"26 3","pages":"302-307"},"PeriodicalIF":2.4,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/25/69/jbc-26-302.PMC10315333.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9805590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictors of Decreased Quality of Life in Breast Cancer Survivors Five Years After Diagnosis.","authors":"Saskia-Laureen Herbert,&nbsp;Felix Flock,&nbsp;Ricardo Felberbaum,&nbsp;Wolfgang Janni,&nbsp;Sanja Löb,&nbsp;Matthias Kiesel,&nbsp;Tanja Schlaiß,&nbsp;Joachim Diessner,&nbsp;Carolin Curtaz,&nbsp;Ralf Joukhadar,&nbsp;Davut Dayan,&nbsp;Lukas Schwentner,&nbsp;Susanne Singer,&nbsp;Achim Wöckel","doi":"10.4048/jbc.2023.26.e23","DOIUrl":"https://doi.org/10.4048/jbc.2023.26.e23","url":null,"abstract":"<p><strong>Purpose: </strong>Due to improved therapy, early diagnosis, and growing incidence rates, the number of long-term breast cancer survivors is increasing. Survivors can still be affected by aftercare, resulting in reduced quality of life (QoL). Thus, in this study, we investigated possible predictors of decreased physical and social functioning in breast cancer survivors.</p><p><strong>Methods: </strong>In a German multicenter prospective study, we enrolled 759 female patients with breast cancer before surgery (t1), and contacted them again 5 years after surgery (t4). Data on QoL were assessed at t4 using the European Organization for Research and Treatment of Cancer QoL Core Questionnaire (EORTC QLQ-C30) and its breast cancer module EORTC QLQ-BR23. Predictors of decreased physical and social functioning were analyzed using logistic regression with odds ratios as effect estimates and 95% confidence intervals. Thresholds for the clinical importance of detrimental effects on QoL were defined according to Giesinger.</p><p><strong>Results: </strong>Questionnaires from 759 patients were retrieved at t1. Of these, 456 participated in the study at t4. Poor QoL 5 years after diagnosis was reported by 20%-50% of the participants. Age, mastectomy, chemotherapy, education, employment, cohabitation, psychiatric comorbidities at t1, anxiety, depression, and intensity of physical activity emerged as predictors of decreased physical and social functioning 5 years after diagnosis.</p><p><strong>Conclusion: </strong>Relief of symptoms and improvement in the QoL should be priorities in aftercare. Detecting patients with a decreased QoL is a rising challenge. Healthcare providers should take special care of patients aged 50-59 years, patients with psychiatric comorbidities and depression, and patients who have undergone mastectomy.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":"26 3","pages":"243-253"},"PeriodicalIF":2.4,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/aa/d6/jbc-26-243.PMC10315334.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9805591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diffusion-Weighted Magnetic Resonance Imaging for Preoperative Evaluation of Patients With Breast Cancer: Protocol of a Prospective, Multicenter, Observational Cohort Study.","authors":"Vivian Youngjean Park,&nbsp;Hee Jung Shin,&nbsp;Bong Joo Kang,&nbsp;Min Jung Kim,&nbsp;Woo Kyung Moon,&nbsp;Sung Eun Song,&nbsp;Su Min Ha","doi":"10.4048/jbc.2023.26.e18","DOIUrl":"https://doi.org/10.4048/jbc.2023.26.e18","url":null,"abstract":"<p><strong>Purpose: </strong>Detection of multifocal, multicentric, and contralateral breast cancers in patients affects surgical management. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) can identify additional foci that were initially undetected by conventional imaging. However, its use is limited owing to low specificity and high false-positive rate. Multiparametric MRI (DCE-MRI + diffusion-weighted [DW] MRI) can increase the specificity. We aimed to describe the protocols of our prospective, multicenter, observational cohort studies designed to compare the diagnostic performance of DCE-MRI and multiparametric MRI for the diagnosis of multifocal, multicentric cancer and contralateral breast cancer in patients with newly diagnosed breast cancer.</p><p><strong>Methods: </strong>Two studies comparing the performance of DCE-MRI and multiparametric MRI for the diagnosis of multifocal, multicentric cancer (NCT04656639) and contralateral breast cancer (NCT05307757) will be conducted. For trial NCT04656639, 580 females with invasive breast cancer candidates for breast conservation surgery whose DCE-MRI showed additional suspicious lesions (breast imaging reporting and data system [BI-RADS] category ≥ 4) on DCE-MRI in the ipsilateral breast will be enrolled. For trial NCT05307757, 1098 females with invasive breast cancer whose DCE-MRI showed contralateral lesions (BI-RADS category ≥ 3 or higher on DCE-MRI) will be enrolled. Participants will undergo 3.0-T DCE-MRI and DW-MRI. The diagnostic performance of DCE-MRI and multiparametric MRI will be compared. The receiver operating characteristic curve, sensitivity, specificity, positive predictive value, and characteristics of the detected cancers will be analyzed. The primary outcome is the difference in the receiver operating characteristic curve between DCE-MRI and multiparametric MRI interpretation. Enrollment completion is expected in 2024, and study results are expected to be presented in 2026.</p><p><strong>Discussion: </strong>This prospective, multicenter study will compare the performance of DCE-MRI versus multiparametric MRI for the preoperative evaluation of multifocal, multicentric, and contralateral breast cancer and is currently in the patient enrollment phase.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov Identifier: NCT04656639, NCT05307757. Registered on April 1 2022.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":"26 3","pages":"292-301"},"PeriodicalIF":2.4,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9f/f8/jbc-26-292.PMC10315329.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10341796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breast Cancer Statistics in Korea, 2019.","authors":"Jung Eun Choi,&nbsp;Zisun Kim,&nbsp;Chan Sub Park,&nbsp;Eun Hwa Park,&nbsp;Sae Byul Lee,&nbsp;Se Kyung Lee,&nbsp;Young Jin Choi,&nbsp;Jaihong Han,&nbsp;Kyu-Won Jung,&nbsp;Hee Jeong Kim,&nbsp;Hyun-Ah Kim","doi":"10.4048/jbc.2023.26.e27","DOIUrl":"https://doi.org/10.4048/jbc.2023.26.e27","url":null,"abstract":"<p><p>This article provides an annual update of Korean breast cancer statistics, including the incidence, tumor stage, type of surgical treatment, and mortality. The data was collected from the Korean Breast Cancer Society registry system and Korean Central Cancer Registry. In 2019, 29,729 women were newly diagnosed with breast cancer. Breast cancer has continued to increase in incidence since 2002 and been the most common cancer in Korean women since 2019. Of the newly diagnosed cases in 2019, 24,820 (83.5%) were of invasive carcinomas, and 4,909 (16.5%) were of carcinoma <i>in situ</i>. The median age of women with breast cancer was 52.8 years, and breast cancer was most commonly diagnosed in the age group of 40-49 years. The number of patients who have undergone breast conserving surgery has continued to increase since 2016, with 68.6% of patients undergoing breast conserving surgery in 2019. The incidence of early-stage breast cancer continues to increase, with stage 0 or I breast cancer accounting for 61.6% of cases. The most common subtype of breast cancer is the hormone receptor-positive human epidermal growth factor receptor 2-negative subtype (63.1%). The 5-year relative survival rate of patients with breast cancer from 2015 to 2019 was 93.6%, with an increase of 14.3% compared to that from 1993 to 1995. This report improves our understanding of breast cancer characteristics in South Korea.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":"26 3","pages":"207-220"},"PeriodicalIF":2.4,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ba/e9/jbc-26-207.PMC10315335.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9747887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inhibition of Tumor Growth and Metastasis by Newcastle Disease Virus Strain P05 in a Breast Cancer Mouse Model.","authors":"Oscar Antonio Ortega-Rivera,&nbsp;Pamela Gallegos-Alcalá,&nbsp;Mariela Jiménez,&nbsp;J Luis Quintanar,&nbsp;Flor Torres-Juarez,&nbsp;Bruno Rivas-Santiago,&nbsp;Susana Del Toro-Arreola,&nbsp;Eva Salinas","doi":"10.4048/jbc.2023.26.e9","DOIUrl":"https://doi.org/10.4048/jbc.2023.26.e9","url":null,"abstract":"<p><strong>Purpose: </strong>Conventional therapies and surgery remain the standard treatment for breast cancer. However, combating the eventual development of metastasis is still a challenge. Newcastle disease virus (NDV) is one of the various species of viruses under clinical evaluation as a vector for oncolytic, gene-, and immune-stimulating therapies. The purpose of this study was to evaluate the antitumor activity of a recombinant NDV (rNDV-P05) in a breast cancer murine model.</p><p><strong>Methods: </strong>Tumors were induced by injecting the cellular suspension (4T1 cell line) subcutaneously. The virus strain P05 was applied three times at intervals of seven days, starting seven days after tumor induction, and was completed 21 days later. Determination of tumor weight, spleen index, and lung metastasis were done after sacrificing the mice. Serum levels of interferon (IFN)-α, IFN-γ, tumor necrosis factor (TNF)-α, and TNF-related apoptosis-inducing ligand (TRAIL) were quantified by enzyme-linked immunosorbent assay. CD8+ infiltrated cells were analyzed by immunofluorescence.</p><p><strong>Results: </strong>rNDV-P05 showed a route-of-administration-dependent effect, demonstrating that the systemic administration of the virus significantly reduces the tumor mass and volume, spleen index, and abundance of metastatic clonogenic colonies in lung tissue, and increases the inhibition rate of the tumor. The intratumoral administration of rNDV-P05 was ineffective for all the parameters evaluated. Antitumor and antimetastatic capability of rNDV-P05 is mediated, at least partially, through its immune-stimulatory effect on the upregulation of TNF-α, TRAIL, IFN-α, and IFN-γ, and its ability to recruit CD8+ T cells into tumor tissue.</p><p><strong>Conclusion: </strong>Systemic treatment with rNDV-P05 decreases the tumoral parameters in the breast cancer murine model.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":"26 2","pages":"186-200"},"PeriodicalIF":2.4,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e6/c8/jbc-26-186.PMC10139849.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9715843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Cancer/Testis Antigen CT45A1 Promotes Transcription of Oncogenic <i>Sulfatase-2</i> Gene in Breast Cancer Cells and Is Sensible Targets for Cancer Therapy.","authors":"Ping Yang,&nbsp;Yingnan Qiao,&nbsp;Huaidong Liao,&nbsp;Yizheng Huang,&nbsp;Mei Meng,&nbsp;Yu Chen,&nbsp;Quansheng Zhou","doi":"10.4048/jbc.2023.26.e5","DOIUrl":"https://doi.org/10.4048/jbc.2023.26.e5","url":null,"abstract":"<p><strong>Purpose: </strong>Invasive breast carcinomas (BRCAs) are highly lethal. The molecular mechanisms underlying progression of invasive BRCAs are unclear, and effective therapies are highly desired. The cancer-testis antigen CT45A1 promotes overexpression of pro-metastatic sulfatase-2 (SULF2) and breast cancer metastasis to the lungs, but its mechanisms are largely unknown. In this study, we aimed to elucidate the mechanism of CT45A1-induced SULF2 overexpression and provide evidence for targeting CT45A1 and SULF2 for breast cancer therapy.</p><p><strong>Methods: </strong>The effect of CT45A1 on SULF2 expression was assessed using reverse transcription polymerase chain reaction and western blot. The mechanism of CT45A1-induced <i>SULF2</i> gene transcription was studied using protein-DNA binding assay and a luciferase activity reporter system. The interaction between CT45A1 and SP1 proteins was assessed using immunoprecipitation and western blot. Additionally, the suppression of breast cancer cell motility by SP1 and SULF2 inhibitors was measured using cell migration and invasion assays.</p><p><strong>Results: </strong>CT45A1 and SULF2 are aberrantly overexpressed in patients with BRCA; importantly, overexpression of CT45A1 is closely associated with poor prognosis. Mechanistically, gene promoter demethylation results in overexpression of both CT45A1 and SULF2. CT45A1 binds directly to the core sequence GCCCCC in the promoter region of <i>SULF2</i> gene and activates the promoter. Additionally, CT45A1 interacts with the oncogenic master transcription factor SP1 to drive <i>SULF2</i> gene transcription. Interestingly, SP1 and SULF2 inhibitors suppress breast cancer cell migration, invasion, and tumorigenicity.</p><p><strong>Conclusion: </strong>Overexpression of CT45A1 is associated with poor prognosis in patients with BRCA. CT45A1 promotes SULF2 overexpression by activating the promoter and interacting with SP1. Additionally, SP1 and SULF2 inhibitors suppress breast cancer cell migration, invasion, and tumorigenesis. Our findings provide new insight into the mechanisms of breast cancer metastasis and highlight CT45A1 and SULF2 as sensible targets for developing novel therapeutics against metastatic breast cancer.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":"26 2","pages":"168-185"},"PeriodicalIF":2.4,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/5f/b3/jbc-26-168.PMC10139848.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9759174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Adjuvant Hormone Therapy on Sleep, Physical Activity, and Quality of Life in Premenopausal Breast Cancer: 12-Month Observational Study.","authors":"Seung Mi Yeo,&nbsp;Ji Young Lim,&nbsp;Seok Won Kim,&nbsp;Byung Joo Chae,&nbsp;Jonghan Yu,&nbsp;Jai Min Ryu,&nbsp;Ji Hye Hwang","doi":"10.4048/jbc.2023.26.e11","DOIUrl":"https://doi.org/10.4048/jbc.2023.26.e11","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to investigate the differences in sleep disturbance changes between patients receiving two hormone therapies (\"tamoxifen plus ovarian function suppression group [T+OFS group]\" versus \"tamoxifen group [T group]\") and the chronological changes in sleep disturbances in each group.</p><p><strong>Methods: </strong>Premenopausal women with unilateral breast cancer who underwent surgery and were scheduled to receive hormone therapy (HT) with tamoxifen alone or with tamoxifen plus gonadotropin-releasing hormone (GnRH) agonist for ovarian function suppression were included. The enrolled patients wore an actigraphy watch for two weeks and completed questionnaires (insomnia, sleep quality, physical activity [PA], and quality of life [QOL]) at five time points: immediately before HT and 2, 5, 8, and 11 months after HT.</p><p><strong>Results: </strong>Among the 39 enrolled patients (21 and 18 patients in the T+OFS group and T group, respectively), 25 (17 and 8 patients in the T+OFS group and T group, respectively) were finally analyzed. There were no differences between the two groups in time-dependent changes in insomnia, sleep quality, total sleep time, rapid eye movement sleep rate, QOL, and PA; however, the severity of hot flashes was significantly higher in the T+OFS group than in the T group. Although the interaction between group and time was not significant, insomnia and sleep quality significantly worsened at 2-5 months of HT when changes over time were analyzed within the T+OFS group. In both the groups, PA and QOL were maintained without significant changes.</p><p><strong>Conclusion: </strong>Unlike tamoxifen alone, tamoxifen plus GnRH agonist initially worsened insomnia and sleep quality, but gradually improved with long-term follow-up. Patients who initially experience insomnia during tamoxifen plus GnRH agonist administration can be reassured based on the results of this study, and active supportive care may be used during this period.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov Identifier: NCT04116827.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":"26 2","pages":"93-104"},"PeriodicalIF":2.4,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/37/c0/jbc-26-93.PMC10139843.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9715844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prediction of Oncotype DX Recurrence Score Using Clinicopathological Variables in Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.","authors":"Min Chong Kim,&nbsp;Sun Young Kwon,&nbsp;Jung Eun Choi,&nbsp;Su Hwan Kang,&nbsp;Young Kyung Bae","doi":"10.4048/jbc.2023.26.e19","DOIUrl":"https://doi.org/10.4048/jbc.2023.26.e19","url":null,"abstract":"<p><strong>Purpose: </strong>Oncotype DX (ODX) is a well-validated multigene assay that is increasingly used in Korean clinical practice. This study aimed to develop a clinicopathological prediction (CPP) model for the ODX recurrence scores (RSs).</p><p><strong>Methods: </strong>A total of 297 patients (study group, n = 175; external validation group, n = 122) with estrogen receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, T1-3N0-1M0 breast cancer, and available ODX test results were included in the study. Risk categorization as determined by ODX RSs concurred with the TAILORx study (low-risk, RS ≤ 25; high-risk, RS > 25). Univariate and multivariate logistic regression analyses were used to assess the relationships between clinicopathological variables and risk stratified by the ODX RSs. A CPP model was constructed based on regression coefficients (β values) for clinicopathological variables significant by multivariate regression analysis.</p><p><strong>Results: </strong>Progesterone receptor (PR) negativity, high Ki-67 index, and nuclear grade (NG) 3 independently predicted high-risk RS, and these variables were used to construct the CPP model. The C-index, which represented the discriminatory ability of our CPP model for predicting a high-risk RS, was 0.915 (95% confidence interval [CI], 0.859-0.971). When the CPP model was applied to the external validation group, the C-index was 0.926 (95% CI, 0.873-0.978).</p><p><strong>Conclusion: </strong>Our CPP model based on PR, Ki-67 index, and NG could aid in the selection of patients with breast cancer requiring an ODX test.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":"26 2","pages":"105-116"},"PeriodicalIF":2.4,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/35/c4/jbc-26-105.PMC10139850.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9759173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}